Peptide · Modulator of integrin alpha-v beta-3 and integrin alpha-v beta-5 · developed by Lisata Therapeutics
CEND-1 (iRGD) is a cyclic nine-amino-acid peptide containing an RGD motif that binds alphav beta3 and alphav beta5 integrins on tumor endothelium. After tumor-specific protease cleavage, its exposed CendR motif binds neuropilin-1, increasing tumor vascular permeability and tissue penetration of co-administered or conjugated agents. It is studied in pancreatic ductal adenocarcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03517176 | Phase 1 | Pancreatic Cancer | Completed | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pancreatic CancerPancreatic Ductal Adenocarcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →